Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease characterized by the progressive destruction of bile ducts, often leading to chronic liver disease and cirrhosis. Currently, there are only two FDA-approved treatments for PBC, but several promising therapies are in development.
This episode of EASL Studio will:
- Address the persistent challenge of managing pruritus in PBC.
- Explore the collaboration between academia and industry in advancing treatments for rare diseases like PBC.
- Speculate on what future treatment plans for PBC may look like.
Moderator: Ana Lleo
Faculty: Phil Troke (GSK Representative), Christophe Hezode (Gilead Representative), Dimitar Tonev (IPSEN Representative)
This EASL Studio is supported by GSK, Gilead, and IPSEN.
Related episodes:
- EASL Studio at the Congress 2024: New therapeutic options and remaining challenges in PBC
- EASL Studio S5E12: PSC and AIH overlap syndrome: does it actually exist?
- EASL Studio S5E4: PBC: The itch we need to scratch
- EASL Studio at the Congress 2023: Challenges and opportunities for patients with PBC: Highlights from EASL Congress 2023
- EASL Studio S3E3: Primary biliary cholangitis: a look at the future landscape of therapy for patients